Document Detail


Efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of daily statin use.
MedLine Citation:
PMID:  20021539     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The objective of this study was to evaluate the efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of a daily dose of statins. Twenty-three patients, previously receiving aggressive statin therapy, were treated twice weekly with rosuvastatin or atorvastatin in different dosages along with ezetimibe as well as daily doses of bile acid sequestrant for a mean period of 4.5 months. The recommended National Cholesterol Education Program Adult Treatment Panel III goals had already been achieved in 78% of patients (n=18) before starting combination pulse therapy. This combination therapy significantly increased high-density lipoprotein cholesterol values by 5.82% (t=2.138, P=.044), while the increases in total cholesterol, low-density lipoprotein cholesterol, triglyceride, and apolipoprotein B levels compared with baseline were not statistically significant. Overall, 3 of 23 patients (13%) discontinued the combination therapy because of muscle-related symptoms over a mean course of 4.5 months of treatment.
Authors:
Kota J Reddy; Manmeet Singh; Richard R Batsell; Joey R Bangit; Misbah S Zaheer; Shirley John; Shajan Varghese; Ronald Molinella
Related Documents :
17599629 - A long-term effect of epalrestat on motor conduction velocity of diabetic patients: ari...
15378139 - Effects of low-dose atorvastatin on vascular responses in patients undergoing percutane...
19157909 - Preoperative statin administration is associated with lower mortality and decreased nee...
18925579 - Influence of ultrasonographers training on prenatal diagnosis of congenital heart disea...
20150839 - The influence of simvastatin on selected inflammatory markers in patients with chronic ...
18629359 - Perioperative use of statins in noncardiac surgery.
19462369 - Early failure of the dual coat cormet 2000 metal on metal acetabular component.
23828559 - Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant ...
23332439 - Integrating buprenorphine maintenance therapy into federally qualified health centers: ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of clinical hypertension (Greenwich, Conn.)     Volume:  11     ISSN:  1751-7176     ISO Abbreviation:  J Clin Hypertens (Greenwich)     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-12-21     Completed Date:  2010-03-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888554     Medline TA:  J Clin Hypertens (Greenwich)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  766-8     Citation Subset:  IM    
Affiliation:
Reddy Cardiac Wellness Sugar Land, 3519 Town Center Boulevard, Sugarland, TX 77479, USA. jrbangit@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Allylamine / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Analysis of Variance
Anticholesteremic Agents / administration & dosage*,  adverse effects,  therapeutic use
Apolipoproteins B / drug effects
Azetidines / administration & dosage*,  adverse effects,  therapeutic use
Cholesterol, LDL / blood,  drug effects
Drug Monitoring
Drug Therapy, Combination
Female
Fluorobenzenes / administration & dosage*,  adverse effects,  therapeutic use
Heptanoic Acids / administration & dosage*,  adverse effects,  therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage,  adverse effects,  therapeutic use
Hyperlipidemias / drug therapy*
Lipids / blood
Male
Middle Aged
Pulse Therapy, Drug
Pyrimidines / administration & dosage*,  adverse effects,  therapeutic use
Pyrroles / administration & dosage*,  adverse effects,  therapeutic use
Retrospective Studies
Sulfonamides / administration & dosage*,  adverse effects,  therapeutic use
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Apolipoproteins B; 0/Azetidines; 0/Cholesterol, LDL; 0/Fluorobenzenes; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipids; 0/Pyrimidines; 0/Pyrroles; 0/Sulfonamides; 107-11-9/Allylamine; 110862-48-1/atorvastatin; 163222-33-1/ezetimibe; 182815-44-7/colesevelam; 287714-41-4/rosuvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pathogenesis and pathophysiology of the cardiometabolic syndrome.
Next Document:  Association of abdominal adiposity with diabetes and cardiovascular disease in Latin America.